Compare LIVE & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | FGEN |
|---|---|---|
| Founded | 1968 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | LIVE | FGEN |
|---|---|---|
| Price | $14.00 | $9.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | 12.2K | ★ 26.2K |
| Earning Date | 12-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | 4.93 | ★ 53.38 |
| Revenue | ★ $444,944,000.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.84 | ★ $0.16 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.25 | $4.85 |
| 52 Week High | $25.88 | $21.94 |
| Indicator | LIVE | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 57.91 |
| Support Level | $9.05 | $8.37 |
| Resistance Level | $17.35 | $9.09 |
| Average True Range (ATR) | 1.55 | 0.45 |
| MACD | 0.77 | 0.17 |
| Stochastic Oscillator | 70.33 | 84.46 |
Live Ventures Inc is a holding company for diversified businesses. It is focused on acquiring and operating profitable companies in various industries. The company operates in the business segments of Retail Entertainment which includes direct sales of entertainment and appliance products and services, Flooring Manufacturing, Steel Manufacturing, which includes the sale of steel plates, ground flat stock, and drill rods, and Corporate and Other. It derives key revenue from the Flooring Manufacturing segment which includes the manufacturing of carpets and rugs, yarn products, as well as a reseller of hard surface flooring products. Geographically the activities are carried out throughout the United States.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.